Mainz Biomed (NASDAQ:QUCY – Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($0.08) EPS for the quarter, meeting analysts’ consensus estimates of ($0.08), FiscalAI reports. The company had revenue of $0.97 million for the quarter.
Mainz Biomed Stock Performance
Shares of NASDAQ QUCY traded down $0.01 during midday trading on Friday, reaching $0.56. 71,704 shares of the company traded hands, compared to its average volume of 6,002,464. Mainz Biomed has a 12 month low of $0.30 and a 12 month high of $4.93. The stock’s 50-day simple moving average is $1.13 and its 200-day simple moving average is $1.26. The firm has a market cap of $8.15 million, a PE ratio of -0.05 and a beta of 2.42.
Wall Street Analyst Weigh In
QUCY has been the topic of several research analyst reports. Weiss Ratings cut shares of Mainz Biomed from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, September 8th. Zacks Research upgraded Mainz Biomed to a “hold” rating in a research note on Tuesday, August 11th. Finally, Litchfield Hills Research upgraded Mainz Biomed to a “strong-buy” rating in a report on Monday, August 10th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Mainz Biomed has a consensus rating of “Hold”.
Get Our Latest Stock Analysis on Mainz Biomed
About Mainz Biomed
Mainz Biomed N.V. is a molecular genetics diagnostics company focused on developing noninvasive tests for the early detection of cancer. The company is headquartered in Mainz, Germany, and its ordinary shares trade on the Nasdaq Capital Market under the symbol QUCY. Its primary product is ColoAlert, a stool-based molecular diagnostic test designed to detect genetic and molecular biomarkers associated with colorectal cancer and advanced adenomas. The test is intended to offer a noninvasive alternative to screening methods that require a procedure, and it has been marketed in Germany and other European markets following receipt of European regulatory clearance.
Recommended Stories
- Five stocks we like better than Mainz Biomed
- Is Buying the NVIDIA Dip a Mistake? 3 Value Stocks Offer a Different Path Forward
- Costco’s Record $30 Dividend Shows Just How Strong Its Cash Machine Is
- Heavy Lifting: Can USA Rare Earth Turn Its First Sales Into Big Profits?
- These 3 Stocks Have Bought Back Billions, But Which Offers the Best Value?
Receive News & Ratings for Mainz Biomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mainz Biomed and related companies with MarketBeat.com's FREE daily email newsletter.
